Anti Vegf Eylea Hd denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for anti vegf eylea hd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Issues a "Not FDA-Approved" Denial for Eylea HD

This type of denial is often the result of a coding, documentation, or formulary-system mismatch rather than a genuine dispute about regulatory status. Eylea HD (high-dose aflibercept) received FDA approval for specific retinal indications; however, Humana's claims system may flag it if the submitted diagnosis code does not match an indication listed in the drug's approved labeling, if the product's NDC or HCPCS code was submitted incorrectly, or if the request was written for an off-label use that requires additional clinical justification.

## Why This Denial Is Appealable

If Eylea HD was prescribed for an FDA-approved indication and submitted with the correct code, this denial is factually incorrect and should be reversed on appeal with straightforward documentation. If the use is off-label, the appeal is still viable: most group health plans are required under applicable law to cover off-label uses supported by recognized compendia (such as Micromedex or the NCCN Compendium) or peer-reviewed literature, and Humana's own coverage policy must be reviewed to confirm its off-label standard.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You are entitled to a full-and-fair review. Submit within the timeframe shown on the denial letter.
• External review: Available through an accredited IRO after final internal denial, generally within four months of that decision.
• Expedited track: Request 72-hour expedited review in writing if retinal disease activity poses a risk of irreversible vision loss while the appeal is pending.

## Concrete Appeal Steps and Timeline

1. Pull the remittance advice and identify the exact denial reason code; confirm whether the issue is an indication mismatch, a coding error, or a true off-label dispute. 2. If a coding error: have the billing team submit a corrected claim with the correct NDC/HCPCS and ICD-10 diagnosis code before or alongside the appeal. 3. If an indication mismatch: obtain the Eylea HD FDA-approved prescribing information and confirm the submitted diagnosis maps to an approved indication. 4. If off-label: gather compendia references and peer-reviewed literature; have the prescribing ophthalmologist write a letter citing the clinical basis. 5. Submit the internal appeal with all supporting documents and request expedited review if clinically urgent.

## Documentation to Gather

• FDA prescribing information: The current Eylea HD label listing approved indications — available from the FDA's Drugs@FDA database.
• Diagnosis documentation: Chart notes and imaging confirming the specific retinal diagnosis, with the ICD-10 code used on the claim.
• Coding verification: Confirmation from the billing team that the correct HCPCS/NDC was submitted.
• Prescriber letter: Explains how the patient's diagnosis maps to the FDA-approved label (or, for off-label use, cites recognized compendia support).
• Humana coverage policy: Obtain the current policy to understand Humana's off-label coverage standard, if applicable.

## Criteria-Mapping Structure

List the FDA-approved indications from the prescribing label alongside the patient's documented diagnosis. In a parallel column, include the chart evidence (imaging date, finding, ICD-10 code submitted). This side-by-side structure directly refutes the claim that the use is not FDA-approved.